Assertio Therapeutics

Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors

Retrieved on: 
Tuesday, November 14, 2023
Johns Hopkins University, Corporation, Integra, Goldman Sachs, Bank, Bank of America, BofA Securities, Morgan Stanley, Patient, Ironwood Pharmaceuticals, Ironwood, Treasury, Growth, Pharmaceutical industry, Assertio Therapeutics, Strategy

As part of the appointment, Assertio has expanded its board to seven seats.

Key Points: 
  • As part of the appointment, Assertio has expanded its board to seven seats.
  • Mr. Emany currently serves as the Chief Financial Officer of Ironwood Pharmaceuticals.
  • “Sravan is a highly regarded financial leader in pharmaceuticals, and we are thrilled to have him join our Board of Directors,” said Peter D. Staple, Chairman of Assertio.
  • I see real opportunity to help the Board and management achieve Assertio’s next chapter of growth and transformation that will deliver meaningful shareholder value,” said Mr. Emany.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRT   

Retrieved on: 
Monday, November 13, 2023
Acquisition, Assertio Therapeutics, ASRT, News, Pomerantz, Cryptocurrency, Indometacin

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).
  • The investigation concerns whether Assertio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter (“Q3”) of 2023.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Rockwell Medical Names Jesse Neri as Senior Vice President, Finance

Retrieved on: 
Wednesday, October 18, 2023
Other Manufacturing, Research, Medical Devices, Packaging, Manufacturing, Biotechnology, General Health, Health, Science, Other Science, Strategic planning, Therapy, Compensated emancipation, Drexel University, Acquisition, Rockwell Medical, Assertio Therapeutics, Multimedia, Senior, Villanova University, Dialysis, Growth, Employment, Business, The Company, Bone marrow, Patient, Pharmaceutical industry, Finance, Żyła

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Jesse Neri has joined the Company as Senior Vice President, Finance.

Key Points: 
  • Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Jesse Neri has joined the Company as Senior Vice President, Finance.
  • View the full release here: https://www.businesswire.com/news/home/20231018055768/en/
    Jesse Neri - Senior Vice President, Finance at Rockwell Medical (Nasdaq:RMTI) (Photo: Business Wire)
    Mr. Neri has over 20 years' experience leading finance functions at both public and private companies.
  • Previously, Mr. Neri served as Senior Vice President of Finance at Zyla Life Sciences, a public pharmaceutical company with annual revenue of $80 million.
  • “I am thrilled to be joining Rockwell Medical as its new head of finance at such an exciting time in the Company's history," said Mr. Neri.

Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals

Retrieved on: 
Thursday, July 27, 2023
ASRT, SPPI, Spectrum Pharmaceuticals, CVR, Patient, Spectrum, Fine chemical, Cryptocurrency, Pharmaceutical industry, Assertio Therapeutics

LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights (CVR) transaction.

Key Points: 
  • LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights (CVR) transaction.
  • “We are pleased to announce the positive voting results of each meeting and look forward to closing the transaction in the coming days,” said Dan Peisert, President and Chief Executive Officer of Assertio.
  • “We believe this transaction provides extensive new growth opportunities and will be accretive to our stockholders in 2024.
  • We plan to provide updated guidance on our second quarter results call, scheduled for August 3.”

Moore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law Firm

Retrieved on: 
Monday, July 3, 2023
PLLC, Spectrum Pharmaceuticals, Assertio Therapeutics, Wall Street, Fraud, Apollo Global Management, Intuition, Security (finance), Bank, Arconic, Syneos Health

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI

Retrieved on: 
Friday, June 30, 2023
Class Action Lawsuit, Professional Services, Legal, Calendar, SPPI, Spectrum Pharmaceuticals, Assertio Therapeutics, KSF, Sale, Spectrum

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

Retrieved on: 
Tuesday, June 27, 2023
GSK, Business development, Rockwell Medical, Drug development, University, Doctor of Philosophy, Cardiovascular disease, Business, AstraZeneca, Dialysis, Rockwell, St. Lawrence University, Investment, Patient, CBO, Assertio Therapeutics, Drug discovery, Biology, Istaroxime, Therapy, Pharmacology, Sanofi Pasteur, Pharmaceutical industry, Windtree Therapeutics

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.

Key Points: 
  • WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.
  • Craig Fraser, Windtree's President and Chief Executive Officer said, “We are pleased to welcome Mark as a new independent director to Windtree's Board of Directors.
  • Mark will be highly complementary to our existing Board of Directors which includes Dan Geffkin, Leslie Williams, Dr.
  • The Company has a number of strategic opportunities and clinical milestones ahead and I look forward to supporting Windtree to help drive value for patients and shareholders."

IMPORTANT ALERT: Halper Sadeh LLC Investigates AMED, ASRT, SYNH, TESS

Retrieved on: 
Sunday, June 25, 2023
Veritas Capital, Sale, Elliott Investment Management, Advertising, Assertio Therapeutics, Spectrum Pharmaceuticals, Lee Equity Partners, Fraud, Security (finance), Amedisys, Syneos Health

If you are an Amedisys shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Amedisys shareholder, click here to learn more about your rights and options .
  • If you are an Assertio shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

ASRT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Assertio Holdings, Inc. Is Fair to Shareholders

Retrieved on: 
Wednesday, June 7, 2023
Class Action Lawsuit, Professional Services, Legal, ASRT, Fraud, Advertising, Security (finance), Assertio Therapeutics

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Assertio Holdings, Inc. (NASDAQ: ASRT) and Spectrum Pharmaceuticals, Inc. is fair to Assertio shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Assertio Holdings, Inc. (NASDAQ: ASRT) and Spectrum Pharmaceuticals, Inc. is fair to Assertio shareholders.
  • The investigation concerns whether Assertio and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Assertio shareholders; and (2) disclose all material information necessary for Assertio shareholders to adequately assess and value the merger consideration.
  • On behalf of Assertio shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook

Retrieved on: 
Tuesday, May 9, 2023
Spectrum Pharmaceuticals, GAAP, EBITDA, Acquisition, Growth, Assertio Therapeutics, EPS, G-CSF, Video game, Pharmaceutical industry, Cryptocurrency, Bank, Security (finance), Diclofenac, Clobazam, Indometacin

LAKE FOREST, Ill., May 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Indocin sales increased 42%, primarily due to the transition of volumes to more profitable commercial channels implemented in October 2022.
  • Sympazan prescriptions achieved a new record in the quarter, following its prior record in the third quarter 2022.
  • GAAP net loss of $3.5 million, compared to GAAP net income of $9.1 million in the prior year quarter.
  • At March 31, 2023, cash and cash equivalents was $68.6 million and outstanding principal amount of convertible debt was $40 million.